1. Sylw/Dadl › Ymchwil › Adolygwyd gan gymheiriaid
2. Cyhoeddwyd

   Pharmacogenomics spotlight commentary: From the United Kingdom to global populations

   Magavern, E. F., Daly, A. K., Gilchrist, A. & Hughes, D., Rhag 2021, Yn: British Journal of Clinical Pharmacology. 87, 12, t. 4546-4548 3 t., 14917.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Sylw/Dadl › adolygiad gan gymheiriaid

3. Golygyddiad › Ymchwil › Adolygwyd gan gymheiriaid
4. Cyhoeddwyd

   Improving Medication Adherence Research Reporting: European Society for Patient Adherence, Compliance and Persistence Medication Adherence Reporting Guideline

   de Geest, S., Zullig, L., Dunbar-Jacobs, J., Hughes, D., Wilson, I. & Vrijens, B., Meh 2019, Yn: Journal of Cardiovascular Nursing. 34, 3, t. 199-200

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Improving medication adherence research reporting: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

   de Geest, S., Zullig, L. L., Dunbar-Jacob, J., Hughes, D., Wilson, I. & Vrijens, B., 1 Ebr 2019, Yn: European Journal of Cardiovascular Nursing. 18, 4, t. 258-259 2 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   Medication adherence research comes of age

   Wright, D. F. B., Sinnappah, K. A. & Hughes, D., Gorff 2023, Yn: British Journal of Clinical Pharmacology. 89, 7, t. 1914-1917

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Medication adherence – key considerations for clinical pharmacologists

   Hughes, D., Ebr 2020, Yn: British Journal of Clinical Pharmacology. 86, 4, t. 628-629 2 t.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Golygyddiad › adolygiad gan gymheiriaid

8. Crynodeb Cyfarfod › Ymchwil › Adolygwyd gan gymheiriaid
9. Cyhoeddwyd

   Cost effectiveness analysis of treatments for children with uncontrolled asthma symptoms despite taking inhaled corticosteroids

   Culeddu, G., Sinha, I., Donegan, S., Maden, M., Cividini, S., Rose, K., Fulton, O., Turner, S., Tudor-Smith, C. & Hughes, D., 27 Hyd 2023, Yn: European Respiratory Journal. 62 , Supplement 67, PA 523.

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Patient preferences for outcomes in clinical trials: implications for medicines optimization

    Holmes, E., Marson, A. G. & Hughes, D., 8 Mai 2017, Yn: Trials. 18 (Suppl 1), O18, t. 192 1 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Crynodeb Cyfarfod › adolygiad gan gymheiriaid

11. Pennod › Ymchwil › Heb ei adolygu gan gymheiriaid
12. Cyhoeddwyd

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

13. Cyhoeddwyd

    Drug evaluation and pharmocoeconomics.

    Hughes, D., Krska, J., Hughes, D. A., Winfield, A. J. (gol.), Rees, J. A. (gol.) & Smith, I. (gol.), 1 Ion 2009, Pharmaceutical Practice: 4th Edition.. 2009 gol. Churchill Livingstone, t. 185-198

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

14. Cyhoeddwyd

    Health economic aspects of patient non-compliance

    Hughes, D., Hughes, D. A., Davies, M. (gol.) & Kermani, F. (gol.), 1 Ion 2006, Patient Compliance: Sweetening the Pill. 2006 gol. Gower Publishing, t. 23-40

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

15. Cyhoeddwyd

    Modelling in health economics

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 141-154

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

16. Cyhoeddwyd

    The future challenges

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 167-174

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod

17. Pennod › Ymchwil › Adolygwyd gan gymheiriaid
18. Cyhoeddwyd

    Review of resource-use measures in UK economic evaluations

    Ridyard, C. & Hughes, D., 2015, PSSRU Unit Costs of Health and Social Care 2015 . Curtis, L. & Burns, A. (gol.). University of Kent, Canterbury, t. 22-31 10 t.

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion Cynhadledd › Pennod › adolygiad gan gymheiriaid

19. Papur › Ymchwil › Heb ei adolygu gan gymheiriaid
20. Cyhoeddwyd

    A parenting programme for children at risk of developing conduct disorder: A cost-effectiveness analysis

    Hughes, D., Edwards, R. T., Ceilleachair, A., Bywater, T., Hughes, D. A. & Hutchings, J., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

21. Cyhoeddwyd

    A prototype agent-based model of antimalarial drug compliance

    Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    A single centre open phase IV study to evaluate the safety and tolerability of chlorproguanil-dapsone when dosed by defined height bands

    Hughes, D., Makanga, M., Winstanley, P. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. Cyhoeddwyd

    A systematic review and empirical analysis of the relation between dose and duration of drug action.

    Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Ion 2009, t. TP40.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

24. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

25. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

26. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Meh 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

27. Cyhoeddwyd

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Mai 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

28. Cyhoeddwyd

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

29. Cyhoeddwyd

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Meh 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

30. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Gorff 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

31. Cyhoeddwyd

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

32. Cyhoeddwyd

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Ebr 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

33. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

34. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

35. Cyhoeddwyd

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

36. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

37. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

38. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

39. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

40. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

41. Cyhoeddwyd

    Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

    Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

42. Cyhoeddwyd

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

43. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

44. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

45. Cyhoeddwyd

    Cost-effectiveness considerations in pharmacogenetics.

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

46. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

47. Cyhoeddwyd

    Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

48. Cyhoeddwyd

    Costs of non-compliance to antipsychotic medications among patients with schizophrenia.

    Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

49. Cyhoeddwyd

    Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

    Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

50. Cyhoeddwyd

    Drug compliance and pharmaceconomics

    Hughes, D. & Hughes, D. A., 1 Rhag 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

51. Cyhoeddwyd

    Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Chwef 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

52. Cyhoeddwyd

    Economic considerations for pharmacogenetic testing

    Hughes, D. & Hughes, D. A., 1 Meh 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

53. Cyhoeddwyd

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

54. Cyhoeddwyd

    Economic evaluation of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

55. Cyhoeddwyd

    Economic evaluation of on-demand maintenance therapy with proton pump inhibitors in patients with symptomatic gastroesophageal reflux disease - a Monte-Carlo analysis for Italy

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Hyd 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

56. Cyhoeddwyd

    Economic evaluation of steroid injections (methylprednisolone) in the treatment of Morton's neuroma: patient-blind randomised trial

    Hughes, D., Thomson, C., Beggs, I., Martin, D., McCaldin, D., Russell, D., Edwards, R. T., Hughes, D. A., Yeo, S. T., Russell, I. T. & Gibson, T. N., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

57. Cyhoeddwyd

    Effects of the abolition of prescription charges in Wales: A preliminary analysis

    Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

58. Cyhoeddwyd

    Eliciting patients' preferences using a discrete choice experiment questionnaire: the role played by qualitative data in questionnaire design

    Hughes, D., Longo, M., Hughes, D. A., Myles, S. & Lisles, C., 1 Maw 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

59. Cyhoeddwyd

    Empirical analysis of the relationship between dose and duration of drug action

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

60. Cyhoeddwyd

    Engaging with the MRC Methodology Hubs – NWHTMR.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

61. Cyhoeddwyd

    Enhancing methodical approaches for studying bilingualism in healthcare communication: report of a trial feasibility study.

    Roberts, G. W., Hughes, D., Roberts, G., Owen, H., Hughes, L., Whitaker, R., Deuchar, M., Hughes, D. A., Llewelyn, S., John, S., Irvine, F., Owen, B. & Rowlands, A., 1 Ion 2010.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

62. Cyhoeddwyd

    Factors influencing user choices to visit either general practitioners or community pharmacists for minor ailments – a discrete choice experiment

    Hughes, D., Hughes, D. A., Myles, S., Longo, M., Lisles, C. & Hood, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

63. Cyhoeddwyd

    Falls and hip-fractures: A cost-effectiveness analysis of risk assessment and interventions for community-dwelling older people

    Hughes, D., Gwynne, D., Hughes, D. A. & Edwards, R. T., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

64. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D. & Hughes, D. A., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

65. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh EQ-5D health status questionnaire

    Hughes, D., 1 Maw 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

66. Cyhoeddwyd

    From efficacy to cost-effectiveness: Impact of patient compliance

    Hughes, D. & Hughes, D. A., 1 Chwef 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

67. Cyhoeddwyd

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Mai 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

68. Cyhoeddwyd

    From efficacy to effectiveness and cost-effectiveness: modelling possibilities

    Hughes, D. & Hughes, D. A., 1 Tach 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

69. Cyhoeddwyd

    Health and economic outcomes: Why compliance matters

    Hughes, D. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

70. Cyhoeddwyd

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Tach 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

71. Cyhoeddwyd

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

72. Cyhoeddwyd

    Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.

    Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

73. Cyhoeddwyd

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Medi 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

74. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales

    Hughes, D. & Hughes, D. A., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

75. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

76. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

77. Cyhoeddwyd

    Impact of the abolition of the prescription charge in Wales.

    Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

78. Cyhoeddwyd

    Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

    Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

79. Cyhoeddwyd

    Integrating compliance and persistence in health economics models

    Hughes, D. & Hughes, D. A., 1 Ion 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

80. Cyhoeddwyd

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

81. Cyhoeddwyd

    Introduction to pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

82. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

83. Cyhoeddwyd

    Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment

    Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Meh 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

84. Cyhoeddwyd

    Methodological issues in the literature on costs of non-compliance in chronic diseases

    Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

85. Cyhoeddwyd

    Modelling changes in first line antimalarial therapy

    Hughes, D. & Hughes, D. A., 1 Medi 2003.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

86. Cyhoeddwyd

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

87. Cyhoeddwyd

    Patient compliance and persistence with prescribed medication: Measurement and health economic impact

    Hughes, D., Koncz, T., Hughes, D. A., Cleemput, I. & Annemans, L., 1 Mai 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

88. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Tach 2002.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

89. Cyhoeddwyd

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Hyd 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

90. Cyhoeddwyd

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

91. Cyhoeddwyd

    Pharmacoeconomic models that incorporate non-compliance

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

92. Cyhoeddwyd

    Pharmacoeconomics appraisals by the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Gorff 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

93. Cyhoeddwyd

    Pharmacoeconomics in Wales: functions of the all Wales medicines strategy group

    Hughes, D. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

94. Cyhoeddwyd

    Pharmacoeconomics of pharmacogenetic testing: azathioprine

    Hughes, D., McAllister, R. & Hughes, D. A., 1 Ebr 2004.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

95. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

96. Cyhoeddwyd

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Medi 2001.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

97. Cyhoeddwyd

    Physchiatrist prescribing preferences and attitudes toward promotion

    Hughes, D., Menkes, D., Davies, R. & Hughes, D. A., 1 Ebr 2006.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

98. Cyhoeddwyd

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

99. Cyhoeddwyd

    Pragmatic trials - design features and implications for clinical decision making

    Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Awst 2000.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

100. Cyhoeddwyd

     Prescription fee exemption research study

     Hughes, D., Myles, S., Hughes, D. A., Routledge, P. & Wales, D. F., 1 Meh 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

101. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Gorff 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

102. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Ion 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

103. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Tach 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

104. Cyhoeddwyd

     Public funding of drugs for orphan diseases

     Hughes, D. & Hughes, D. A., 1 Tach 2005.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

105. Cyhoeddwyd

     Public meetings of the NICE appraisals committee

     Hughes, D. & Hughes, D. A., 1 Rhag 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

106. Cyhoeddwyd

     Quantitative risk-benefit analysis

     Hughes, D. & Hughes, D. A., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

107. Cyhoeddwyd

     Rationing of drugs for rare diseases

     Hughes, D. & Hughes, D. A., 1 Ebr 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

108. Cyhoeddwyd

     Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

     Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Maw 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

109. Cyhoeddwyd

     The all wales medicines strategy group: assessments and appraisals

     Hughes, D. & Hughes, D. A., 1 Tach 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

110. Cyhoeddwyd

     The assessment, determinants & economics of medication compliance & persistence

     Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

111. Cyhoeddwyd

     The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

     Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

112. Cyhoeddwyd

     The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

     Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

113. Cyhoeddwyd

     The economics of evergreening.

     Hughes, D. & Hughes, D. A., 1 Ion 2009.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

114. Cyhoeddwyd

     The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

     Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

115. Cyhoeddwyd

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

     Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Tach 2000.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

116. Cyhoeddwyd

     The pharmacokinetic profile of Warfarn: a systematic review

     Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

117. Cyhoeddwyd

     The population pharmacokinetics of lapdap

     Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Tach 2002.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

118. Cyhoeddwyd

     Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

     Hughes, D. & Hughes, D. A., 1 Tach 2006.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

119. Cyhoeddwyd

     Use of PK-PD modelling to predict the impact of non-compliance

     Hughes, D. & Hughes, D. A., 1 Tach 2003.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

120. Cyhoeddwyd

     What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

     Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

121. Papur › Ymchwil › Adolygwyd gan gymheiriaid
122. Cyhoeddwyd

     A Systematic Review of Patient Preferences for Subcutaneous Medications

     Ridyard, C., Dawoud, D. & Hughes, D., Tach 2013.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

123. Cyhoeddwyd

     Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

     Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Tach 2015.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

124. Cyhoeddwyd

     Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

     Ridyard, C. & Hughes, D., Tach 2013.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

125. Cyhoeddwyd

     Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation

     Ridyard, C. & Hughes, D., Tach 2013.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

126. Cyhoeddwyd

     Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

     Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Tach 2013.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Papur › adolygiad gan gymheiriaid

127. Murlen › Ymchwil › Adolygwyd gan gymheiriaid
128. Cyhoeddwyd

     Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

     Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Medi 2017.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

129. Cyhoeddwyd

     Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials

     Culeddu, G., Hughes, D. & Welton, N., 10 Gorff 2017.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

130. Cyhoeddwyd

     Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

     Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 Mai 2017, t. P265. 1 t.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

131. Cyhoeddwyd

     Health Economics Analysis Plans: Where Are We Now?

     Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Tach 2016, t. A397. 1 t.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

132. Cyhoeddwyd

     Health economics analysis plans: the current state of play

     Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 Mai 2017, t. P144. 1 t.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

133. Cyhoeddwyd

     Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

     Ridyard, C. & Hughes, D., 7 Mai 2017, t. P141. 1 t.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Murlen › adolygiad gan gymheiriaid

134. Crynodeb › Ymchwil › Adolygwyd gan gymheiriaid
135. Cyhoeddwyd

     Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

     Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Medi 2017, t. 22-23.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Crynodeb › adolygiad gan gymheiriaid

136. Arall › Ymchwil › Adolygwyd gan gymheiriaid
137. Cyhoeddwyd

     Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

     Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

     Allbwn ymchwil: Cyfraniad at gynhadledd › Arall › adolygiad gan gymheiriaid

138. Adroddiad Comisiwn › Ymchwil › Heb ei adolygu gan gymheiriaid
139. Cyhoeddwyd

     A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

     Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

140. Cyhoeddwyd

     AWMSG criteria for appraising new medicines.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

141. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

142. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

143. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

144. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

145. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

146. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

147. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

148. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

149. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

150. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

151. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

152. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

153. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

154. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

155. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

156. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

157. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

158. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

159. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

160. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

161. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

162. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

163. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

164. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

165. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

166. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

167. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

168. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

169. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

170. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

171. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

172. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

173. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

174. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

175. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

176. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

177. Cyhoeddwyd

     All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

     Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

178. Cyhoeddwyd

     Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.

     Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

179. Cyhoeddwyd

     Follow-up of cancer patients in primary care versus secondary care: systematic review.

     Hughes, D., Lewis, R., Neal, R., Williams, N., France, B., Wilkinson, C., Hendry, M., Russell, D., Hughes, D. A., Russell, I. T., Stuart, N. S. & Weller, D., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

180. Cyhoeddwyd

     Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

     Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

181. Cyhoeddwyd

     Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

     Hughes, D. & Hughes, D. A., 1 Ion 2002, 2002 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

182. Cyhoeddwyd

     Improving Outcomes for People with Brain and Other CNS Tumours: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Priedane, E., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

183. Cyhoeddwyd

     Improving Outcomes for People with Sarcoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 1 Ion 2006, 2006 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

184. Cyhoeddwyd

     Improving Outcomes for People with Skin Tumours including Melanoma: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Hughes, D. A. & Edwards, R. T., 21 Chwef 2006, Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

185. Cyhoeddwyd

     Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

     Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

186. Cyhoeddwyd

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Belgium.

     Hughes, D. & Hughes, D. A., 1 Ion 2004, 2004 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

187. Cyhoeddwyd

     Internationalisation of cost-effectiveness model for on-demand use of proton pump inhibitors - Sweden.

     Hughes, D. & Hughes, D. A., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

188. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

189. Cyhoeddwyd

     Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

     Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

190. Cyhoeddwyd

     Policy on ultra-orphan drugs.

     Hughes, D. & Hughes, D. A., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

191. Cyhoeddwyd

     Public health interventions to promote mental well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Windle, G., Hughes, D. A., Linck, P., Morgan, R., Burholt, V., Edwards, R. T., Reeves, C., Yeo, S. T., Woods, R. T. & Russell, I. T., 1 Ion 2007, 2007 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

192. Cyhoeddwyd

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.

     Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

193. Cyhoeddwyd

     Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.

     Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Ion 2008, 2008 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

194. Cyhoeddwyd

     The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

     Hughes, D. & Hughes, D. A., 1 Ion 2001, 2001 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

195. Cyhoeddwyd

     Welsh Health Economics Network (WHEN): Scoping Report.

     Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Ion 2005, 2005 gol. Unknown.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

196. Cyhoeddwyd

     What is the effectiveness and cost-effectiveness of interventions in reducing the harms for children and young people who have been exposed to domestic violence or abuse: a rapid review.

     Spencer, L., Hendry, A., Makanjuola, A., Pisavadia, K., Davies, J., Albustami, M., Anthony, B., Wilkinson, C., Fitzsimmons, D., Hughes, D., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 10 Mai 2023, 79 t.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

197. Adroddiad Comisiwn › Ymchwil › Adolygwyd gan gymheiriaid
198. Cyhoeddwyd

     What innovations can address inequalities experienced by women and girls due to the COVID-19 pandemic across the different areas of life/domains: work, health, living standards, personal security, participation and education? Report number – RR00027 (January 2022). Gender Inequalities: COVID-19 initiatives

     Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Pisavadia, K., Davies, J., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 15 Ion 2022, Health and Care Research Wales.

     Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn › adolygiad gan gymheiriaid

199. Adoddiad Arall › Ymchwil › Heb ei adolygu gan gymheiriaid
200. Cyhoeddwyd

     RES00019. Wales COVID-19 Evidence Centre. A rapid evidence summary indicating the evidence of the inverse care law in social care in Wales and has this been exacerbated by the COVID-19 pandemic?

     Spencer, L., Hendry, A., Makanjuola, A., Hughes, D., Wilkinson, C., Pisavadia, K., Davies, J., Fitzsimmons, D. & Edwards, R. T., Chwef 2022, Welsh Government. 33 t.

     Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall

201. Cyhoeddwyd

     RES00038. Wales COVID-19 Evidence Centre. A rapid evidence summary of the cost impact of Long COVID on employment and caring responsibilities

     Spencer, L., Hendry, A., Davies, J., Pisavadia, K., Hughes, D. & Edwards, R. T., Mai 2022, Welsh Government. 18 t.

     Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall

202. Adoddiad Arall › Ymchwil › Adolygwyd gan gymheiriaid
203. Cyhoeddwyd

     Have infection control and prevention measures resulted in any adverse outcomes for care home and domiciliary care residents and staff? Report number: RR_00018 (November 2021)

     Spencer, L., Hartfiel, N., Hendry, A., Anthony, B., Makanjuola, A., Bray, N., Hughes, D., Wilkinson, C., Fitzsimmons, D. & Edwards, R. T., 1 Tach 2021, 36 t.

     Allbwn ymchwil: Llyfr/Adroddiad › Adoddiad Arall › adolygiad gan gymheiriaid

204. Safe Gwe / Cyhoeddiad Gwe › Ymchwil
205. Cyhoeddwyd

     Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment

     Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008

     Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe

206. Erthygl adolygu › Ymchwil › Adolygwyd gan gymheiriaid
207. Cyhoeddwyd

     A Systematic Review of Economic Evaluations of Advanced Therapy Medicinal Products

     Lloyd Williams, H. & Hughes, D., Meh 2021, Yn: British Journal of Clinical Pharmacology. 87, 6, t. 2428-2443 16 t.

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid

208. Cyhoeddwyd

     Evidence to support inclusion of pharmacogenetic biomarkers in randomised controlled trials

     Johnson, D., Jorgensen, A., Hughes, D. & Pirmohamed, M., 1 Medi 2019, Yn: Journal of Personalized Medicine. 9, 3, 19 t., 42.

     Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid

209. Rhagargraffiad › Ymchwil
210. Cyhoeddwyd

     The costs and cost-effectiveness of different service models of palliatice care, focusing on end of life care: A rapid review

     Spencer, L., Anthony, B., Davies, J., Pisavadia, K., Gillen, E., Noyes, J., Fitzsimmons, D., Lewis, R., Cooper, A., Hughes, D., Edwards, R. T. & Edwards, A., 7 Maw 2024, MedRxiv, 118 t.

     Allbwn ymchwil: Papur gweithio › Rhagargraffiad

211. Cyhoeddwyd

     What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review

     Spencer, L., Hendry, A., Makanjuola, A., Anthony, B., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 28 Ion 2023, 34 t. (MedRxiv).

     Allbwn ymchwil: Papur gweithio › Rhagargraffiad

212. Cyhoeddwyd

     What is the long-term impact of COVID-19 on the Health-Related Quality of Life of individuals with mild symptoms (or non-hospitalised): A rapid review

     Spencer, L., Hendry, A., Makanjuola, A., Davies, J., Pisavadia, K., Hughes, D., Fitzsimmons, D., Wilkinson, C., Edwards, R. T., Lewis, R., Cooper, A. & Edwards, A., 9 Medi 2022, Health and Care Research Wales, 47 t.

     Allbwn ymchwil: Papur gweithio › Rhagargraffiad